J. D. Mount, R. W. Herzog, D. M. Tillson, S. A. Goodman, N. Robinson et al., Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy, Blood, vol.99, issue.8, pp.2670-2676, 2002.
DOI : 10.1182/blood.V99.8.2670

G. Ronzitti, G. Bortolussi, R. Van-dijk, F. Collaud, S. Charles et al., A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome, Molecular Therapy - Methods & Clinical Development, vol.3, p.16049, 2016.
DOI : 10.1038/mtm.2016.49
URL : https://hal.archives-ouvertes.fr/hal-01474146

A. C. Nathwani, C. Rosales, J. Mcintosh, G. Rastegarlari, D. Nathwani et al., Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid Proteins, Molecular Therapy, vol.19, issue.5, pp.876-885, 2011.
DOI : 10.1038/mt.2010.274

L. Guiner, C. Montus, M. Servais, L. Cherel, Y. Francois et al., Forelimb Treatment in a Large Cohort of Dystrophic Dogs Supports Delivery of a Recombinant AAV for Exon Skipping in Duchenne Patients, Molecular Therapy, vol.22, issue.11, pp.1923-1935, 2014.
DOI : 10.1038/mt.2014.151

V. R. Arruda, H. H. Stedman, V. Haurigot, G. Buchlis, S. Baila et al., Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B, Blood, vol.115, issue.23, pp.4678-4688, 2010.
DOI : 10.1182/blood-2009-12-261156

K. D. Foust, E. Nurre, C. L. Montgomery, A. Hernandez, C. M. Chan et al., Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes, Nature Biotechnology, vol.94, issue.1, pp.59-65, 2009.
DOI : 10.1172/JCI22922

A. C. Nathwani, E. G. Tuddenham, S. Rangarajan, C. Rosales, J. Mcintosh et al., Adenovirus-Associated Virus Vector???Mediated Gene Transfer in Hemophilia B, New England Journal of Medicine, vol.365, issue.25, pp.2357-2365, 2011.
DOI : 10.1056/NEJMoa1108046

A. C. Nathwani, U. M. Reiss, E. G. Tuddenham, C. Rosales, P. Chowdary et al., Longterm safety and efficacy of factor IX gene therapy in hemophilia B, N. Engl. J. Med, vol.371, 1994.

C. S. Manno, G. F. Pierce, V. R. Arruda, B. Glader, M. Ragni et al., Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response, Nature Medicine, vol.24, issue.3, pp.342-347, 2006.
DOI : 10.1002/hep.1840200104

L. A. George, S. K. Sullivan, A. Giermasz, J. E. Rasko, B. J. Samelson-jones et al., Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant, New England Journal of Medicine, vol.377, issue.23, pp.2215-2227, 2017.
DOI : 10.1056/NEJMoa1708538

W. Miesbach, K. Meijer, M. Coppens, P. Kampmann, R. Klamroth et al., Gene therapy with adeno-associated virus vector 5???human factor IX in adults with hemophilia B, Blood, vol.131, issue.9, 2017.
DOI : 10.1182/blood-2017-09-804419

S. Rangarajan, L. Walsh, W. Lester, D. Perry, B. Madan et al., AAV5???Factor VIII Gene Transfer in Severe Hemophilia A, New England Journal of Medicine, vol.377, issue.26, pp.2519-2530, 2017.
DOI : 10.1056/NEJMoa1708483

S. Boutin, V. Monteilhet, P. Veron, C. Leborgne, O. Benveniste et al., Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors, Human Gene Therapy, vol.21, issue.6, pp.704-712, 2010.
DOI : 10.1089/hum.2009.182

F. Mingozzi, Y. Chen, S. C. Edmonson, S. Zhou, R. M. Thurlings et al., Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue, Gene Therapy, vol.20, issue.4, pp.417-424, 2013.
DOI : 10.1038/sj.gt.3300680

Y. S. Tseng, K. V. Vliet, L. Rao, R. Mckenna, B. J. Byrne et al., Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies, Journal of Virological Methods, vol.236, pp.105-110, 2016.
DOI : 10.1016/j.jviromet.2016.07.009

B. L. Gurda, C. Raupp, R. Popa-wagner, M. Naumer, N. H. Olson et al., Mapping a Neutralizing Epitope onto the Capsid of Adeno-Associated Virus Serotype 8, Journal of Virology, vol.86, issue.15, pp.7739-7751, 2012.
DOI : 10.1128/JVI.00218-12
URL : http://jvi.asm.org/content/86/15/7739.full.pdf

B. L. Gurda, M. A. Dimattia, E. B. Miller, A. Bennett, R. Mckenna et al., Capsid Antibodies to Different Adeno-Associated Virus Serotypes Bind Common Regions, Journal of Virology, vol.87, issue.16, pp.9111-9124, 2013.
DOI : 10.1128/JVI.00622-13
URL : http://jvi.asm.org/content/87/16/9111.full.pdf

H. Jiang, L. B. Couto, S. Patarroyo-white, T. Liu, D. Nagy et al., Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy, Blood, vol.108, issue.10, pp.3321-3328, 2006.
DOI : 10.1182/blood-2006-04-017913

C. Li, N. Narkbunnam, R. J. Samulski, A. Asokan, G. Hu et al., Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia, Gene Therapy, vol.81, issue.3, pp.288-294, 2012.
DOI : 10.1128/JVI.00529-07
URL : http://www.nature.com/gt/journal/v19/n3/pdf/gt201190a.pdf

K. Erles, P. Sebökovà, and J. R. Schlehofer, Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV), Journal of Medical Virology, vol.71, issue.3, pp.406-411, 1999.
DOI : 10.1099/0022-1317-78-6-1441

R. Calcedo, H. Morizono, L. Wang, R. Mccarter, J. He et al., ABSTRACT, Clinical and Vaccine Immunology, vol.18, issue.9, pp.1586-1588, 2011.
DOI : 10.1128/CVI.05107-11

S. L. Murphy, H. Li, F. Mingozzi, D. E. Sabatino, D. J. Hui et al., Diverse IgG subclass responses to adeno-associated virus infection and vector administration, Journal of Medical Virology, vol.11, issue.1, pp.65-74, 2009.
DOI : 10.1016/j.ymthe.2005.02.014
URL : http://onlinelibrary.wiley.com/doi/10.1002/jmv.21360/pdf

L. Wang, R. Calcedo, H. Wang, P. Bell, R. Grant et al., The Pleiotropic Effects of Natural AAV Infections on Liver-directed Gene Transfer in Macaques, Molecular Therapy, vol.18, issue.1, pp.126-134, 2010.
DOI : 10.1038/mt.2009.245

A. G. Johansson, T. Løvdal, K. E. Magnusson, T. Berg, and T. Skogh, Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats, Hepatology, vol.24, issue.1, pp.169-175, 1996.
DOI : 10.1053/jhep.1996.v24.pm0008707258

A. Gonzalez-quintela, R. Alende, F. Gude, J. Campos, J. Rey et al., Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities, Clinical & Experimental Immunology, vol.34, issue.1, pp.42-50, 2008.
DOI : 10.1093/alcalc/34.6.830

S. Jolles, W. A. Sewell, and S. A. Misbah, Clinical uses of intravenous immunoglobulin, Clinical and Experimental Immunology, vol.126, issue.1, pp.1-11, 2005.
DOI : 10.1016/S0887-7963(03)00038-5
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2249.2005.02834.x/pdf

A. Meliani, C. Leborgne, S. Triffault, L. Jeanson-leh, P. Veron et al., Reporter System, Human Gene Therapy Methods, vol.26, issue.2, pp.45-53, 2015.
DOI : 10.1089/hgtb.2015.037

E. Ayuso, F. Mingozzi, J. Montane, X. Leon, X. M. Anguela et al., High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency, Gene Therapy, vol.17, issue.4, 2010.
DOI : 10.1182/blood-2007-03-080093
URL : http://www.nature.com/gt/journal/v17/n4/pdf/gt2009157a.pdf

, Gene Ther, vol.17, pp.503-510

L. Galibert and O. Merten, Latest developments in the large-scale production of adeno-associated virus vectors in insect cells toward the treatment of neuromuscular diseases, Journal of Invertebrate Pathology, vol.107, pp.80-93, 2011.
DOI : 10.1016/j.jip.2011.05.008

F. Mingozzi, X. M. Anguela, G. Pavani, Y. Chen, R. J. Davidson et al., Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys, Science Translational Medicine, vol.109, issue.4, 2013.
DOI : 10.1182/blood-2006-03-010181

B. Heyman, Regulation of Antibody Responses via Antibodies, Complement, and Fc Receptors, Annual Review of Immunology, vol.18, issue.1, pp.709-737, 2000.
DOI : 10.1146/annurev.immunol.18.1.709

F. B. Bouche, O. T. Ertl, and C. P. Muller, Neutralizing B Cell Response in Measles, Viral Immunology, vol.15, issue.3, pp.451-471, 2002.
DOI : 10.1089/088282402760312331

C. S. Manno, A. J. Chew, S. Hutchison, P. J. Larson, R. W. Herzog et al., AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B, Blood, vol.101, issue.8, pp.2963-2972, 2003.
DOI : 10.1182/blood-2002-10-3296

A. K. Bevan, S. Duque, K. D. Foust, P. R. Morales, L. Braun et al., Systemic Gene Delivery in Large Species for Targeting Spinal Cord, Brain, and Peripheral Tissues for Pediatric Disorders, Molecular Therapy, vol.19, issue.11, 1971.
DOI : 10.1038/mt.2011.157

F. Mingozzi and K. A. High, Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges, Nature Reviews Genetics, vol.6, issue.5, pp.341-355, 2011.
DOI : 10.1002/jgm.554

D. 'avola, D. López-franco, E. Sangro, B. Pañeda, A. Grossios et al., Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria, J. Hepatol, vol.65, pp.776-783, 2016.

C. D. Scallan, H. Jiang, T. Liu, S. Patarroyo-white, J. M. Sommer et al., Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice, Blood, vol.107, issue.5, pp.1810-1817, 2006.
DOI : 10.1182/blood-2005-08-3229

C. N. Jenne and P. Kubes, Immune surveillance by the liver, Nature Immunology, vol.119, issue.10, pp.996-1006, 2013.
DOI : 10.1126/science.1092385

I. N. Crispe, Liver antigen-presenting cells, Journal of Hepatology, vol.54, issue.2, pp.357-365, 2011.
DOI : 10.1016/j.jhep.2010.10.005
URL : https://doi.org/10.1016/j.jhep.2010.10.005

D. L. Mallery, W. A. Mcewan, S. R. Bidgood, G. J. Towers, C. M. Johnson et al., Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21), Proc. Natl. Acad. Sci. USA, 2010.
DOI : 10.1093/emboj/cdf691
URL : http://www.pnas.org/content/107/46/19985.full.pdf

L. Falese, K. Sandza, B. Yates, S. Triffault, S. Gangar et al., Strategy to detect pre-existing immunity to AAV gene therapy, Gene Therapy, vol.269, issue.12, pp.768-778, 2017.
DOI : 10.1038/gt.2014.47
URL : https://www.nature.com/articles/gt201795.pdf

P. Veron, C. Leborgne, V. Monteilhet, S. Boutin, S. Martin et al., Humoral and Cellular Capsid-Specific Immune Responses to Adeno-Associated Virus Type 1 in Randomized Healthy Donors, The Journal of Immunology, vol.188, issue.12, pp.6418-6424, 2012.
DOI : 10.4049/jimmunol.1200620
URL : http://www.jimmunol.org/content/188/12/6418.full.pdf

L. Evgin, S. A. Acuna, C. Tanese-de-souza, M. Marguerie, C. G. Lemay et al., Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques, Molecular Therapy, vol.23, issue.6, pp.1066-1076, 2015.
DOI : 10.1038/mt.2015.49

Y. Nishimura, T. Igarashi, N. Haigwood, R. Sadjadpour, R. J. Plishka et al., Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies, Journal of Virology, vol.76, issue.5, pp.2123-2130, 2002.
DOI : 10.1128/jvi.76.5.2123-2130.2002

R. Calcedo, L. H. Vandenberghe, G. Gao, J. Lin, W. et al., Worldwide Epidemiology of Neutralizing Antibodies to Adeno???Associated Viruses, The Journal of Infectious Diseases, vol.2, issue.3, pp.381-390, 2009.
DOI : 10.1126/science.1154258

C. H. Miao, K. Ohashi, G. A. Patijn, L. Meuse, X. Ye et al., Inclusion of the Hepatic Locus Control Region, an Intron, and Untranslated Region Increases and Stabilizes Hepatic Factor IX Gene Expression in Vivo but Not in Vitro, Molecular Therapy, vol.1, issue.6, pp.522-532, 2000.
DOI : 10.1006/mthe.2000.0075

M. Ferrand, S. Da-rocha, G. Corre, A. Galy, and F. Boisgerault, Serotype-specific Binding Properties and Nanoparticle Characteristics Contribute to the Immunogenicity of rAAV1 Vectors, Molecular Therapy, vol.23, issue.6, pp.1022-1033, 2015.
DOI : 10.1038/mt.2015.59